COVID-19
COVID-19 Vaccine Response in Multiple Sclerosis Patients Treated with Ofatumumab
New research conducted at the University of Pennsylvania sheds light on the impact of ofatumumab, an anti-CD20 B-cell-depleting monoclonal antibody, on vaccination response in patients with relapsing multiple sclerosis (RMS). The study aimed to assess humoral immune response (HIR) to COVID-19 mRNA vaccination in patients treated with ofatumumab. Results show